Galapagos spinout Coultreon raises $125M for new take on SIK inhibition
Coultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the burgeoning pipeline-in-a-pill approach to autoimmune diseases. The Tuesday morning Series ...
Pierre Raboisson, Coultreon Biopharma CEO April 28, 2026 07:00 AM EDT FinancingStartups Galapagos spinout Coultreon raises $125M for new take on SIK inhibition Kyle LaHucik Biotech Correspondent Coultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that